Baer Sarah, Rebert Mathieu, Burger Pauline, Mandel Jean-Louis, Villeneuve Nathalie, Gibaud Marc, Altuzarra Cecilia, Villega Frédéric, Cances Claude, Lacan Laure, Nguyen Sylvie, Lesca Gaëtan, Isnard Hervé, Allani-Essid Nouha, Laugel Vincent, Coutelle Romain, de Saint Martin Anne
Department of Pediatric Neurology, Strasbourg University Hospital, Hautepierre Hospital, Centre de Référence des Épilepsies Rares, Strasbourg, France; Institut de Génétique et de Biologie Moléculaire et Cellulaire, Université de Strasbourg, INSERM U1258, CNRS UMR7104, Illkirch, 67400, France.
Department of Pediatric Neurology, Strasbourg University Hospital, Hautepierre Hospital, Centre de Référence des Épilepsies Rares, Strasbourg, France; Physical Medicine and Rehabilitation Department, Clemenceau Institute and Strasbourg University Hospital, Strasbourg University, Strasbourg, France.
Eur J Paediatr Neurol. 2025 Jan;54:121-129. doi: 10.1016/j.ejpn.2025.01.003. Epub 2025 Jan 10.
SLC6A1 (Solute Carrier Family 6 Member 1) variants are associated with SLC6A1-neurodevelopmental disorders (SLC6A1-NDD), which manifest as early-onset epilepsy, intellectual developmental disorder, and autism spectrum disorder. There have been over 300 reported cases so far. A retrospective analysis of 14 patients with de novo SLC6A1 variants was conducted to assess their developmental milestones, epilepsy progression, antiseizure medication, and, for some, a comprehensive neurodevelopmental evaluation. Data from 14 additional families were also collected using the GenIDA participatory database, aiming to better characterize the natural history of genetic forms of NDDs. Most patients exhibited normal early motor development, but delays in communication and language skills were observed. Their intellectual functioning varied, mostly falling within the low average to moderate intellectual developmental disorder range, with a predominant expressive and receptive language disorder. More than half of the group displayed autistic features, particularly stereotypic behavior. Behavioral disorders such as hyperactivity, anxiety, impulsivity, or inhibition were common concerns for parents. The first seizures occurred between 14 months and 5 years, mainly presenting as generalized seizures (atonic falls, absences, atypical absences, myoclonic-atonic seizures). EEG results frequently showed bursts of rhythmic delta activity, persisting from childhood to adulthood, with epilepsy primarily responding well to antiseizure medication in most of the reported cases. This study exhibited a distinct electroclinical and neurodevelopmental phenotype in young children, suggesting the importance of early genetic testing for SLC6A1-NDD diagnosis.
溶质载体家族6成员1(SLC6A1)变异与SLC6A1神经发育障碍(SLC6A1-NDD)相关,其表现为早发性癫痫、智力发育障碍和自闭症谱系障碍。迄今为止,已有超过300例报告病例。对14例新发SLC6A1变异患者进行了回顾性分析,以评估他们的发育里程碑、癫痫进展、抗癫痫药物治疗情况,以及部分患者的全面神经发育评估。还使用GenIDA参与性数据库收集了另外14个家庭的数据,旨在更好地描述神经发育障碍遗传形式的自然病史。大多数患者早期运动发育正常,但观察到沟通和语言技能延迟。他们的智力功能各不相同,大多处于低平均水平到中度智力发育障碍范围内,主要表现为表达性和接受性语言障碍。超过一半的患者表现出自闭症特征,尤其是刻板行为。多动、焦虑、冲动或抑制等行为障碍是家长普遍关注的问题。首次癫痫发作发生在14个月至5岁之间,主要表现为全身性发作(失张力跌倒、失神发作、非典型失神发作、肌阵挛-失张力发作)。脑电图结果经常显示有节律的δ活动爆发,从儿童期持续到成年期,在大多数报告病例中,癫痫对抗癫痫药物治疗反应良好。这项研究在幼儿中展现出独特的电临床和神经发育表型,表明早期基因检测对SLC6A1-NDD诊断的重要性。